Literature DB >> 10411893

Hot-spot mutants of p53 core domain evince characteristic local structural changes.

K B Wong1, B S DeDecker, S M Freund, M R Proctor, M Bycroft, A R Fersht.   

Abstract

Most of the oncogenic mutations in the tumor suppressor p53 map to its DNA-binding (core) domain. It is thus a potential target in cancer therapy for rescue by drugs. To begin to understand how mutation inactivates p53 and hence to provide a structural basis for drug design, we have compared structures of wild-type and mutant p53 core domains in solution by NMR spectroscopy. Structural changes introduced by five hot-spot mutations (V143A, G245S, R248Q, R249S, and R273H) were monitored by chemical-shift changes. Only localized changes are observed for G245S, R248Q, R249S, and R273H, suggesting that the overall tertiary folds of these mutant proteins are similar to that of wild type. Structural changes in R273H are found mainly in the loop-sheet-helix motif and the loop L3 of the core domain. Mutations in L3 (G245S, R248Q, and R249S) introduce structural changes in the loop L2 and L3 as well as terminal residues of strands 4, 9, and 10. It is noteworthy that R248Q, which is often regarded as a contact mutant that affects only interactions with DNA, introduces structural changes as extensive as the other loop L3 mutations (G245S and R249S). These changes suggest that R248Q is also a structural mutant that perturbs the structure of loop L2-L3 regions of the p53 core domain. In contrast to other mutants, replacement of the core residue valine 143 to alanine causes chemical-shift changes in almost all residues in the beta-sandwich and the DNA-binding surface. Long-range effects of V143A mutation may affect the specificity of DNA binding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10411893      PMCID: PMC17534          DOI: 10.1073/pnas.96.15.8438

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis.

Authors:  P Friedlander; Y Haupt; C Prives; M Oren
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

2.  Amino-acid-type-selective triple-resonance experiments.

Authors:  V Dötsch; R E Oswald; G Wagner
Journal:  J Magn Reson B       Date:  1996-01

3.  Thermodynamic stability of wild-type and mutant p53 core domain.

Authors:  A N Bullock; J Henckel; B S DeDecker; C M Johnson; P V Nikolova; M R Proctor; D P Lane; A R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

Review 4.  Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels.

Authors:  B Miroux; J E Walker
Journal:  J Mol Biol       Date:  1996-07-19       Impact factor: 5.469

5.  Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations.

Authors:  R K Brachmann; K Yu; Y Eby; N P Pavletich; J D Boeke
Journal:  EMBO J       Date:  1998-04-01       Impact factor: 11.598

6.  Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.

Authors:  C J Di Como; C Prives
Journal:  Oncogene       Date:  1998-05-14       Impact factor: 9.867

7.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.

Authors:  N P Pavletich; K A Chambers; C O Pabo
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

8.  Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions.

Authors:  M Piotto; V Saudek; V Sklenár
Journal:  J Biomol NMR       Date:  1992-11       Impact factor: 2.835

9.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.

Authors:  J V Gannon; R Greaves; R Iggo; D P Lane
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

10.  p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.

Authors:  T Unger; M M Nau; S Segal; J D Minna
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

View more
  67 in total

1.  Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations.

Authors:  P V Nikolova; K B Wong; B DeDecker; J Henckel; A R Fersht
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

2.  A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants.

Authors:  Assaf Friedler; Lars O Hansson; Dmitry B Veprintsev; Stefan M V Freund; Thomas M Rippin; Penka V Nikolova; Mark R Proctor; Stefan Rüdiger; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

3.  A stochastic algorithm for global optimization and for best populations: a test case of side chains in proteins.

Authors:  Meir Glick; Anwar Rayan; Amiram Goldblum
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

4.  CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90.

Authors:  Stefan Rudiger; Stefan M V Freund; Dmitry B Veprintsev; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-05       Impact factor: 11.205

Review 5.  Utilizing NMR to study the structure of growth-inhibitory proteins.

Authors:  Francesca Marassi
Journal:  Methods Mol Biol       Date:  2003

6.  p53 differentially inhibits cell growth depending on the mechanism of telomere maintenance.

Authors:  Zaineb R Abdul Razak; Robert J Varkonyi; Michelle Kulp-McEliece; Corrado Caslini; Joseph R Testa; Maureen E Murphy; Dominique Broccoli
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

7.  Allele-specific p53 mutant reactivation.

Authors:  Xin Yu; Alexei Vazquez; Arnold J Levine; Darren R Carpizo
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

8.  Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients.

Authors:  Jon A Kenniston; Mark A Lemmon
Journal:  EMBO J       Date:  2010-08-10       Impact factor: 11.598

9.  Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis.

Authors:  Xiaojie Xu; Zhongyi Fan; Lei Kang; Juqiang Han; Chengying Jiang; Xiaofei Zheng; Ziman Zhu; Huabo Jiao; Jing Lin; Kai Jiang; Lihua Ding; Hao Zhang; Long Cheng; Hanjiang Fu; Yi Song; Ying Jiang; Jiahong Liu; Rongfu Wang; Nan Du; Qinong Ye
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

10.  Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide.

Authors:  Natalia Issaeva; Assaf Friedler; Przemyslaw Bozko; Klas G Wiman; Alan R Fersht; Galina Selivanova
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.